市場調査レポート

商品コード

1344273

API中間体市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

API Intermediate Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

出版日: 2023年06月01日 | 発行: Allied Market Research

| ページ情報: 英文 390 Pages | 納期: 2～3営業日

価格

Cloud Access (Single User License)

USD 3,570 560,989円

レポートのクラウドアクセスでご利用頂けるライセンスです。ウェブポータルで配信され、60日間レポートにアクセスできます。この期間を過ぎるとレポートへのアクセスは失効します。コンテンツのダウンロード、印刷、共有、コピー＆ペーストはできません。

PDF (Business License)

USD 5,730 900,412円

レポートPDFをご利用いただけるライセンスです。ライセンスを付与されたPCでのみレポートPDFの保存、表示、利用が可能です。PDFl内のテキスト等のコピー＆ペーストは可能です。印刷は5回可能です。追加料金を支払うことで、2～5ユーザーを収容できるようにアップグレードできます。

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

USD 9,600 1,508,544円

レポートPDFとExcel定量データをひとつの企業、及びその子会社でご利用頂けるライセンスです。ライセンスを付与されたPCでのみレポートPDFとExcelの保存、表示、利用が可能です。PDFとExcel内のテキスト等のコピー＆ペーストは可能です。PDFとExcelの印刷回数の制限はありません。印刷したレポートの利用は企業、及びその子会社内にて共有可能です。無料でレポートのアップデートがご利用いただけます。

価格表記: USDを日本円(税抜)に換算

本日の銀行送金レート: 1USD=157.14円

全表示
概要
図表
目次

概要

サンプル依頼リストに入れる

Allied Market Research発行の調査レポート「API中間体市場」によると、API中間体市場は2022年に1,394億米ドルと評価され、2023年から2032年にかけてCAGR 7.4%で成長し、2032年には2,850億米ドルに達すると推定されています。

医薬品有効成分（API）は、医薬品の製造に使用される物質または物質の組み合わせです。医薬品有効成分の製剤化に使用される原料はAPI中間体として知られています。API中間体は、原薬の製造過程で生成される物質です。 API中間体には化学中間体と原薬中間体の2種類があります。原薬中間体とは、医薬品の製造過程で生成される化学物質または化合物を指します。一方、化学中間体とは、医薬品、農薬、染料、ポリマー、その他の工業製品を含む様々な化学物質の合成や製造過程で生成される化合物や物質のことです。

API中間体市場の成長は、慢性疾患の有病率の上昇と老人人口の増加が牽引しています。APIおよび中間体は、腫瘍学、心臓病学、中枢神経系（CNS）および神経学、整形外科学、呼吸器学、消化器学、腎臓病学、眼科学、内分泌学などの疾患の治療に使用される高品質の医薬品に応用されています。原薬と中間体は、より革新的な製品を導入することで、より持続可能なヘルスケアシステムを構築できる可能性があります。そのため、心疾患などの慢性疾患に罹患する人口の増加がAPI中間体の需要を煽り、市場の成長を後押しすると予想されます。例えば、英国心臓財団によると、英国では2022年に約1,139,140人が心臓・循環器系疾患に罹患しています。同じ情報源によると、2022年に英国で心臓および循環器系疾患に罹患した人口は、男性が約650,681人、女性が約488,320人でした。

さらに、米国心臓協会によると、2020年には2億4,410万人が虚血性心疾患（IHD）に罹患していると推定されています。同資料によると、IHDは女性よりも男性に多く、それぞれ1億4,100万人と1億310万人でした。

市場の定義と範囲
主な調査結果
- 影響要因
- 主な投資機会
ポーターのファイブフォース分析
市場力学
- 促進要因
  - 慢性疾患の増加
  - 市場企業のプレゼンスの高さ
  - 老年人口の急増
- 抑制要因
  - 厳しい政府規制
- 機会
  - バイオ医薬品産業の急成長
  - 市場企業による主要戦略の採用の増加
COVID-19による市場への影響分析

第4章 API中間体市場：タイプ別

概要
原薬中間体
化学中間体

第5章 API中間体市場：用途別

概要
鎮痛薬
抗感染症薬
抗糖尿病薬
心血管治療薬
抗がん剤
その他

第6章 API中間体市場：エンドユーザー別

概要
バイオテクノロジーおよび製薬企業
CMO
その他

第7章 API中間体市場：地域別

概要
北米
- 米国
- カナダ
- メキシコ
欧州
- ドイツ
- フランス
- 英国
- イタリア
- スペイン
- その他欧州
アジア太平洋
- 日本
- 中国
- インド
- オーストラリア
- 韓国
- その他アジア太平洋地域
ラテンアメリカ・中東・アフリカ
- ブラジル
- サウジアラビア
- 南アフリカ
- その他の地域

第8章競争情勢

イントロダクション
主要成功戦略
主要10企業の製品マッピング
競合ダッシュボード
競合ヒートマップ
主要企業のポジショニング、2022年

第9章企業プロファイル

Anyang General Chemical Co., Ltd.
Sandoo Pharmaceuticals
Evonik Industries AG.
Shree Ganesh Remedies Limited
Cambrex Corporation
Zeal & Innovation in Medicine
Cation Pharma
Espee
Hikal Ltd
Pfizer Inc.

図表

LIST OF TABLES

TABLE 01. GLOBAL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 02. API INTERMEDIATE MARKET FOR BULK DRUG INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
TABLE 03. API INTERMEDIATE MARKET FOR CHEMICAL INTERMEDIATES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GLOBAL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 05. API INTERMEDIATE MARKET FOR ANALGESICS, BY REGION, 2022-2032 ($MILLION)
TABLE 06. API INTERMEDIATE MARKET FOR ANTI-INFECTIVE DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. API INTERMEDIATE MARKET FOR ANTIDIABETIC DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 08. API INTERMEDIATE MARKET FOR CARDIOVASCULAR DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 09. API INTERMEDIATE MARKET FOR ANTICANCER DRUGS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 12. API INTERMEDIATE MARKET FOR BIOTECH AND PHARMACEUTICAL COMPANIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. API INTERMEDIATE MARKET FOR CMO, BY REGION, 2022-2032 ($MILLION)
TABLE 14. API INTERMEDIATE MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. API INTERMEDIATE MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 21. U.S. API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 22. U.S. API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 23. CANADA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 24. CANADA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 25. CANADA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 26. MEXICO API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 27. MEXICO API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 29. EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 30. EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 32. EUROPE API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 34. GERMANY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 36. FRANCE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 37. FRANCE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 39. UK API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 40. UK API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 41. UK API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 42. ITALY API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 43. ITALY API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 44. ITALY API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 45. SPAIN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 46. SPAIN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. JAPAN API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 56. JAPAN API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 57. JAPAN API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 58. CHINA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 59. CHINA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 60. CHINA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 61. INDIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 62. INDIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 63. INDIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 73. LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 74. LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 76. LAMEA API INTERMEDIATE MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 78. BRAZIL API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA API INTERMEDIATE MARKET, BY TYPE, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA API INTERMEDIATE MARKET, BY APPLICATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA API INTERMEDIATE MARKET, BY END USER, 2022-2032 ($MILLION)
TABLE 89. ANYANG GENERAL CHEMICAL CO., LTD.: KEY EXECUTIVES
TABLE 90. ANYANG GENERAL CHEMICAL CO., LTD.: COMPANY SNAPSHOT
TABLE 91. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT SEGMENTS
TABLE 92. ANYANG GENERAL CHEMICAL CO., LTD.: PRODUCT PORTFOLIO
TABLE 93. SANDOO PHARMACEUTICALS: KEY EXECUTIVES
TABLE 94. SANDOO PHARMACEUTICALS: COMPANY SNAPSHOT
TABLE 95. SANDOO PHARMACEUTICALS: PRODUCT SEGMENTS
TABLE 96. SANDOO PHARMACEUTICALS: PRODUCT PORTFOLIO
TABLE 97. EVONIK INDUSTRIES AG.: KEY EXECUTIVES
TABLE 98. EVONIK INDUSTRIES AG.: COMPANY SNAPSHOT
TABLE 99. EVONIK INDUSTRIES AG.: PRODUCT SEGMENTS
TABLE 100. EVONIK INDUSTRIES AG.: PRODUCT PORTFOLIO
TABLE 101. SHREE GANESH REMEDIES LIMITED: KEY EXECUTIVES
TABLE 102. SHREE GANESH REMEDIES LIMITED: COMPANY SNAPSHOT
TABLE 103. SHREE GANESH REMEDIES LIMITED: PRODUCT SEGMENTS
TABLE 104. SHREE GANESH REMEDIES LIMITED: SERVICE SEGMENTS
TABLE 105. SHREE GANESH REMEDIES LIMITED: PRODUCT PORTFOLIO
TABLE 106. CAMBREX CORPORATION: KEY EXECUTIVES
TABLE 107. CAMBREX CORPORATION: COMPANY SNAPSHOT
TABLE 108. CAMBREX CORPORATION: PRODUCT SEGMENTS
TABLE 109. CAMBREX CORPORATION: SERVICE SEGMENTS
TABLE 110. CAMBREX CORPORATION: PRODUCT PORTFOLIO
TABLE 111. CAMBREX CORPORATION: KEY STRATERGIES
TABLE 112. ZEAL & INNOVATION IN MEDICINE: KEY EXECUTIVES
TABLE 113. ZEAL & INNOVATION IN MEDICINE: COMPANY SNAPSHOT
TABLE 114. ZEAL & INNOVATION IN MEDICINE: PRODUCT SEGMENTS
TABLE 115. ZEAL & INNOVATION IN MEDICINE: PRODUCT PORTFOLIO
TABLE 116. CATION PHARMA: KEY EXECUTIVES
TABLE 117. CATION PHARMA: COMPANY SNAPSHOT
TABLE 118. CATION PHARMA: PRODUCT SEGMENTS
TABLE 119. CATION PHARMA: PRODUCT PORTFOLIO
TABLE 120. ESPEE: KEY EXECUTIVES
TABLE 121. ESPEE: COMPANY SNAPSHOT
TABLE 122. ESPEE: PRODUCT SEGMENTS
TABLE 123. ESPEE: PRODUCT PORTFOLIO
TABLE 124. HIKAL LTD: KEY EXECUTIVES
TABLE 125. HIKAL LTD: COMPANY SNAPSHOT
TABLE 126. HIKAL LTD: PRODUCT SEGMENTS
TABLE 127. HIKAL LTD: PRODUCT PORTFOLIO
TABLE 128. PFIZER INC.: KEY EXECUTIVES
TABLE 129. PFIZER INC.: COMPANY SNAPSHOT
TABLE 130. PFIZER INC.: PRODUCT SEGMENTS
TABLE 131. PFIZER INC.: PRODUCT PORTFOLIO

LIST OF FIGURES

FIGURE 01. API INTERMEDIATE MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF API INTERMEDIATE MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN API INTERMEDIATE MARKET (2023-2032)
FIGURE 04. LOW BARGAINING POWER OF SUPPLIERS
FIGURE 05. LOW THREAT OF NEW ENTRANTS
FIGURE 06. LOW THREAT OF SUBSTITUTES
FIGURE 07. LOW INTENSITY OF RIVALRY
FIGURE 08. LOW BARGAINING POWER OF BUYERS
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALAPI INTERMEDIATE MARKET
FIGURE 09. API INTERMEDIATE MARKET, BY TYPE, 2022(%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR BULK DRUG INTERMEDIATES, BY COUNTRY 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CHEMICAL INTERMEDIATES, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. API INTERMEDIATE MARKET, BY APPLICATION, 2022(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANALGESICS, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTI-INFECTIVE DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTIDIABETIC DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CARDIOVASCULAR DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR ANTICANCER DRUGS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. API INTERMEDIATE MARKET, BY END USER, 2022(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR BIOTECH AND PHARMACEUTICAL COMPANIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR CMO, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF API INTERMEDIATE MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. API INTERMEDIATE MARKET BY REGION, 2022
FIGURE 24. U.S. API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 33. JAPAN API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 34. CHINA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 35. INDIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 36. AUSTRALIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF ASIA-PACIFIC API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 39. BRAZIL API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 40. SAUDI ARABIA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF LAMEA API INTERMEDIATE MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: API INTERMEDIATE MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
FIGURE 50. EVONIK INDUSTRIES AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. EVONIK INDUSTRIES AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. EVONIK INDUSTRIES AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 53. PFIZER INC.: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 54. PFIZER INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 55. PFIZER INC.: REVENUE SHARE BY REGION, 2022 (%)

Product Code: A02308

According to a new report published by Allied Market Research, titled, "API Intermediate Market," The api intermediate market was valued at $139.4 billion in 2022, and is estimated to reach $285 billion by 2032, growing at a CAGR of 7.4% from 2023 to 2032.

Active pharmaceutical ingredients (APIs) are substances or combination of substances used to manufacture a drug product. The raw material used in formulation of active pharmaceutical ingredients is known as API intermediates. API intermediates are material produced in the process of manufacturing of API. There are two types of API intermediates, which includes chemical intermediates and bulk drug intermediates. A bulk drug intermediate refers to a chemical substance or compound that is produced during the manufacturing process of a pharmaceutical drug. A chemical intermediate, on the other hand, is a compound or substance that is produced during the synthesis or production of various chemicals, including pharmaceuticals, agrochemicals, dyes, polymers, and other industrial products.

The growth of the API intermediates market is driven by rise in the prevalence of chronic diseases and increase in number of geriatric populations. APIs and intermediates possess application in high-quality drugs used for the treatment of diseases, such as oncology, cardiology, central nervous system (CNS) and neurology, orthopedic, pulmonology, gastroenterology, nephrology, ophthalmology, and endocrinology. APIs and intermediates can potentially create a more sustainable healthcare system by introducing more innovative products. Thus, rise in number of populations suffering from chronic diseases, such as cardiac diseases, is anticipated to fuel the demand for API intermediates and boosts the market growth. For instance, according to the British Heart Foundation, around 1,139,140 people were suffering from heart and circulatory diseases in the UK in 2022. As per the same source, around 650,681 male and 488,320 female population were suffering from heart and circulatory diseases in the UK in 2022.

Moreover, according to the American Heart Association, 244.1 million people were estimated to be living with ischemic heart disease (IHD) in 2020. As per the same source, IHD was more prevalent in males than in females, 141.0 and 103.1 million people, respectively.

In addition, the American Cancer Society reported that, around 1,918,030 new cases of cancer detected in the U.S. in 2022. Moreover, World Cancer Research Fund International, (WCRFI), reported that around 18.1 million new cancer cases were detected in 2020 globally. Furthermore, rise in number of populations suffering from pulmonary and gastrointestinal disorders is expected to increase the demand for API intermediates and fuels the growth of the market. The global initiative for chronic obstructive lung disease (GOLD), in 2022, reported that 200 million people had chronic obstructive pulmonary disease (COPD), of which about 3.2 million die each year, making it the third-leading cause of death globally. In addition, as per the same source, asthma is one of the most common non-communicable diseases, globally affecting 262 million people in 2022.

High presence of companies who manufacture API intermediates is anticipated to boost the growth of the market. For instance, Shubham Specialty Products, Akums Drugs & Pharmaceuticals Ltd., Vasoya Industrial Pvt. Lmt., Corey Organics, Icon Pharma Chem, and SLN Pharmachem are some of the key market players who manufacture API intermediates.

However, the high cost associated with the acquisition of biopharmaceutical drugs is a major factor hampering the growth of global API intermediates market. Also, the high cAPItal investment required to produce API intermediates is expected to restrain the market growth.

On the contrary, rise in initiative taken by government of different countries such as India, China, Japan, and others, for development of healthcare infrastructure and increase in expenditure for development of API intermediates manufacturing units are anticipated to offer remunerative opportunities for the expansion of the market during the forecast period.

The global API intermediates market is segmented into type, application, end user, and region. By type, the market is divided into bulk drug intermediates and chemical intermediates. On the basis of application, the market is divided into analgesics, anti-infective drugs, antidiabetic drugs, cardiovascular drugs, anticancer drugs and others. By end user, the market is segmented into biotech & pharmaceutical companies, CMO and research laboratories. Region-wise, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Some of the major companies that operate in the global API intermediates market include: Anyang General Chemical Co., Ltd., Sandoo Pharmaceuticals, Evonik Industries AG, Shree Ganesh Remedies Limited, Pfizer, Cambrex Corporation, Zeal & Innovation in Medicine, cation pharma, Hikal Ltd., and Espee.

Key Benefits For Stakeholders

This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the API intermediate market analysis from 2022 to 2032 to identify the prevailing API intermediate market opportunities.
The market research is offered along with information related to key drivers, restraints, and opportunities.
Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
In-depth analysis of the API intermediate market segmentation assists to determine the prevailing market opportunities.
Major countries in each region are mapped according to their revenue contribution to the global market.
Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
The report includes the analysis of the regional as well as global API intermediate market trends, key players, market segments, application areas, and market growth strategies.

Key Market Segments

By Type

Bulk Drug Intermediates
Chemical Intermediates

By Application

Analgesics
Anti-Infective Drugs
Antidiabetic Drugs
Cardiovascular Drugs
Anticancer Drugs
Others

By End User

Biotech and Pharmaceutical Companies
CMO
Others

By Region

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
Asia-Pacific
- Japan
- China
- India
- Australia
- South Korea
- Rest of Asia-Pacific
LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA

Key Market Players:

Anyang General Chemical Co., Ltd.
Cambrex Corporation
Cation Pharma
Espee
Evonik Industries AG.
Hikal Ltd
Pfizer Inc.
Sandoo Pharmaceuticals
Shree Ganesh Remedies Limited
Zeal & Innovation in Medicine

CHAPTER 1: INTRODUCTION

1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
- 1.4.1. Primary research
- 1.4.2. Secondary research
- 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

2.1. CXO Perspective

CHAPTER 3: MARKET OVERVIEW

3.1. Market definition and scope
3.2. Key findings
- 3.2.1. Top impacting factors
- 3.2.2. Top investment pockets
3.3. Porter's five forces analysis
- 3.3.1. Low bargaining power of suppliers
- 3.3.2. Low threat of new entrants
- 3.3.3. Low threat of substitutes
- 3.3.4. Low intensity of rivalry
- 3.3.5. Low bargaining power of buyers
3.4. Market dynamics
- 3.4.1. Drivers
  - 3.4.1.1. Rise in prevalence of chronic disease
  - 3.4.1.2. High presence of market players
  - 3.4.1.3. Surge in number of geriatric populations

3.4.2. Restraints
- 3.4.2.1. Stringent government rules

3.4.3. Opportunities
- 3.4.3.1. Rapid growth of biopharmaceutical industry
- 3.4.3.2. Increase in adoptions of key strategies by market players.

3.5. COVID-19 Impact Analysis on the market

CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE

4.1. Overview
- 4.1.1. Market size and forecast
4.2. Bulk Drug Intermediates
- 4.2.1. Key market trends, growth factors and opportunities
- 4.2.2. Market size and forecast, by region
- 4.2.3. Market share analysis by country
4.3. Chemical Intermediates
- 4.3.1. Key market trends, growth factors and opportunities
- 4.3.2. Market size and forecast, by region
- 4.3.3. Market share analysis by country

CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION

5.1. Overview
- 5.1.1. Market size and forecast
5.2. Analgesics
- 5.2.1. Key market trends, growth factors and opportunities
- 5.2.2. Market size and forecast, by region
- 5.2.3. Market share analysis by country
5.3. Anti-Infective Drugs
- 5.3.1. Key market trends, growth factors and opportunities
- 5.3.2. Market size and forecast, by region
- 5.3.3. Market share analysis by country
5.4. Antidiabetic Drugs
- 5.4.1. Key market trends, growth factors and opportunities
- 5.4.2. Market size and forecast, by region
- 5.4.3. Market share analysis by country
5.5. Cardiovascular Drugs
- 5.5.1. Key market trends, growth factors and opportunities
- 5.5.2. Market size and forecast, by region
- 5.5.3. Market share analysis by country
5.6. Anticancer Drugs
- 5.6.1. Key market trends, growth factors and opportunities
- 5.6.2. Market size and forecast, by region
- 5.6.3. Market share analysis by country
5.7. Others
- 5.7.1. Key market trends, growth factors and opportunities
- 5.7.2. Market size and forecast, by region
- 5.7.3. Market share analysis by country

CHAPTER 6: API INTERMEDIATE MARKET, BY END USER

6.1. Overview
- 6.1.1. Market size and forecast
6.2. Biotech and Pharmaceutical Companies
- 6.2.1. Key market trends, growth factors and opportunities
- 6.2.2. Market size and forecast, by region
- 6.2.3. Market share analysis by country
6.3. CMO
- 6.3.1. Key market trends, growth factors and opportunities
- 6.3.2. Market size and forecast, by region
- 6.3.3. Market share analysis by country
6.4. Others
- 6.4.1. Key market trends, growth factors and opportunities
- 6.4.2. Market size and forecast, by region
- 6.4.3. Market share analysis by country

CHAPTER 7: API INTERMEDIATE MARKET, BY REGION

7.1. Overview
- 7.1.1. Market size and forecast By Region
7.2. North America
- 7.2.1. Key trends and opportunities
- 7.2.2. Market size and forecast, by Type
- 7.2.3. Market size and forecast, by Application
- 7.2.4. Market size and forecast, by End User
- 7.2.5. Market size and forecast, by country
  - 7.2.5.1. U.S.
  - 7.2.5.1.1. Key market trends, growth factors and opportunities
  - 7.2.5.1.2. Market size and forecast, by Type
  - 7.2.5.1.3. Market size and forecast, by Application
  - 7.2.5.1.4. Market size and forecast, by End User
  - 7.2.5.2. Canada
  - 7.2.5.2.1. Key market trends, growth factors and opportunities
  - 7.2.5.2.2. Market size and forecast, by Type
  - 7.2.5.2.3. Market size and forecast, by Application
  - 7.2.5.2.4. Market size and forecast, by End User
  - 7.2.5.3. Mexico
  - 7.2.5.3.1. Key market trends, growth factors and opportunities
  - 7.2.5.3.2. Market size and forecast, by Type
  - 7.2.5.3.3. Market size and forecast, by Application
  - 7.2.5.3.4. Market size and forecast, by End User
7.3. Europe
- 7.3.1. Key trends and opportunities
- 7.3.2. Market size and forecast, by Type
- 7.3.3. Market size and forecast, by Application
- 7.3.4. Market size and forecast, by End User
- 7.3.5. Market size and forecast, by country
  - 7.3.5.1. Germany
  - 7.3.5.1.1. Key market trends, growth factors and opportunities
  - 7.3.5.1.2. Market size and forecast, by Type
  - 7.3.5.1.3. Market size and forecast, by Application
  - 7.3.5.1.4. Market size and forecast, by End User
  - 7.3.5.2. France
  - 7.3.5.2.1. Key market trends, growth factors and opportunities
  - 7.3.5.2.2. Market size and forecast, by Type
  - 7.3.5.2.3. Market size and forecast, by Application
  - 7.3.5.2.4. Market size and forecast, by End User
  - 7.3.5.3. UK
  - 7.3.5.3.1. Key market trends, growth factors and opportunities
  - 7.3.5.3.2. Market size and forecast, by Type
  - 7.3.5.3.3. Market size and forecast, by Application
  - 7.3.5.3.4. Market size and forecast, by End User
  - 7.3.5.4. Italy
  - 7.3.5.4.1. Key market trends, growth factors and opportunities
  - 7.3.5.4.2. Market size and forecast, by Type
  - 7.3.5.4.3. Market size and forecast, by Application
  - 7.3.5.4.4. Market size and forecast, by End User
  - 7.3.5.5. Spain
  - 7.3.5.5.1. Key market trends, growth factors and opportunities
  - 7.3.5.5.2. Market size and forecast, by Type
  - 7.3.5.5.3. Market size and forecast, by Application
  - 7.3.5.5.4. Market size and forecast, by End User
  - 7.3.5.6. Rest of Europe
  - 7.3.5.6.1. Key market trends, growth factors and opportunities
  - 7.3.5.6.2. Market size and forecast, by Type
  - 7.3.5.6.3. Market size and forecast, by Application
  - 7.3.5.6.4. Market size and forecast, by End User
7.4. Asia-Pacific
- 7.4.1. Key trends and opportunities
- 7.4.2. Market size and forecast, by Type
- 7.4.3. Market size and forecast, by Application
- 7.4.4. Market size and forecast, by End User
- 7.4.5. Market size and forecast, by country
  - 7.4.5.1. Japan
  - 7.4.5.1.1. Key market trends, growth factors and opportunities
  - 7.4.5.1.2. Market size and forecast, by Type
  - 7.4.5.1.3. Market size and forecast, by Application
  - 7.4.5.1.4. Market size and forecast, by End User
  - 7.4.5.2. China
  - 7.4.5.2.1. Key market trends, growth factors and opportunities
  - 7.4.5.2.2. Market size and forecast, by Type
  - 7.4.5.2.3. Market size and forecast, by Application
  - 7.4.5.2.4. Market size and forecast, by End User
  - 7.4.5.3. India
  - 7.4.5.3.1. Key market trends, growth factors and opportunities
  - 7.4.5.3.2. Market size and forecast, by Type
  - 7.4.5.3.3. Market size and forecast, by Application
  - 7.4.5.3.4. Market size and forecast, by End User
  - 7.4.5.4. Australia
  - 7.4.5.4.1. Key market trends, growth factors and opportunities
  - 7.4.5.4.2. Market size and forecast, by Type
  - 7.4.5.4.3. Market size and forecast, by Application
  - 7.4.5.4.4. Market size and forecast, by End User
  - 7.4.5.5. South Korea
  - 7.4.5.5.1. Key market trends, growth factors and opportunities
  - 7.4.5.5.2. Market size and forecast, by Type
  - 7.4.5.5.3. Market size and forecast, by Application
  - 7.4.5.5.4. Market size and forecast, by End User
  - 7.4.5.6. Rest of Asia-Pacific
  - 7.4.5.6.1. Key market trends, growth factors and opportunities
  - 7.4.5.6.2. Market size and forecast, by Type
  - 7.4.5.6.3. Market size and forecast, by Application
  - 7.4.5.6.4. Market size and forecast, by End User
7.5. LAMEA
- 7.5.1. Key trends and opportunities
- 7.5.2. Market size and forecast, by Type
- 7.5.3. Market size and forecast, by Application
- 7.5.4. Market size and forecast, by End User
- 7.5.5. Market size and forecast, by country
  - 7.5.5.1. Brazil
  - 7.5.5.1.1. Key market trends, growth factors and opportunities
  - 7.5.5.1.2. Market size and forecast, by Type
  - 7.5.5.1.3. Market size and forecast, by Application
  - 7.5.5.1.4. Market size and forecast, by End User
  - 7.5.5.2. Saudi Arabia
  - 7.5.5.2.1. Key market trends, growth factors and opportunities
  - 7.5.5.2.2. Market size and forecast, by Type
  - 7.5.5.2.3. Market size and forecast, by Application
  - 7.5.5.2.4. Market size and forecast, by End User
  - 7.5.5.3. South Africa
  - 7.5.5.3.1. Key market trends, growth factors and opportunities
  - 7.5.5.3.2. Market size and forecast, by Type
  - 7.5.5.3.3. Market size and forecast, by Application
  - 7.5.5.3.4. Market size and forecast, by End User
  - 7.5.5.4. Rest of LAMEA
  - 7.5.5.4.1. Key market trends, growth factors and opportunities
  - 7.5.5.4.2. Market size and forecast, by Type
  - 7.5.5.4.3. Market size and forecast, by Application
  - 7.5.5.4.4. Market size and forecast, by End User

CHAPTER 8: COMPETITIVE LANDSCAPE

8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022

CHAPTER 9: COMPANY PROFILES

9.1. Anyang General Chemical Co., Ltd.
- 9.1.1. Company overview
- 9.1.2. Key Executives
- 9.1.3. Company snapshot
- 9.1.4. Operating business segments
- 9.1.5. Product portfolio
9.2. Sandoo Pharmaceuticals
- 9.2.1. Company overview
- 9.2.2. Key Executives
- 9.2.3. Company snapshot
- 9.2.4. Operating business segments
- 9.2.5. Product portfolio
9.3. Evonik Industries AG.
- 9.3.1. Company overview
- 9.3.2. Key Executives
- 9.3.3. Company snapshot
- 9.3.4. Operating business segments
- 9.3.5. Product portfolio
- 9.3.6. Business performance
9.4. Shree Ganesh Remedies Limited
- 9.4.1. Company overview
- 9.4.2. Key Executives
- 9.4.3. Company snapshot
- 9.4.4. Operating business segments
- 9.4.5. Product portfolio
9.5. Cambrex Corporation
- 9.5.1. Company overview
- 9.5.2. Key Executives
- 9.5.3. Company snapshot
- 9.5.4. Operating business segments
- 9.5.5. Product portfolio
- 9.5.6. Key strategic moves and developments
9.6. Zeal & Innovation in Medicine
- 9.6.1. Company overview
- 9.6.2. Key Executives
- 9.6.3. Company snapshot
- 9.6.4. Operating business segments
- 9.6.5. Product portfolio
9.7. Cation Pharma
- 9.7.1. Company overview
- 9.7.2. Key Executives
- 9.7.3. Company snapshot
- 9.7.4. Operating business segments
- 9.7.5. Product portfolio
9.8. Espee
- 9.8.1. Company overview
- 9.8.2. Key Executives
- 9.8.3. Company snapshot
- 9.8.4. Operating business segments
- 9.8.5. Product portfolio
9.9. Hikal Ltd
- 9.9.1. Company overview
- 9.9.2. Key Executives
- 9.9.3. Company snapshot
- 9.9.4. Operating business segments
- 9.9.5. Product portfolio
- 9.9.6. Business performance
9.10. Pfizer Inc.
- 9.10.1. Company overview
- 9.10.2. Key Executives
- 9.10.3. Company snapshot
- 9.10.4. Operating business segments
- 9.10.5. Product portfolio
- 9.10.6. Business performance

API中間体市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

API Intermediate Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第4章 API中間体市場：タイプ別

第5章 API中間体市場：用途別

第6章 API中間体市場：エンドユーザー別

第7章 API中間体市場：地域別

第8章競争情勢

第9章企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE

CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION

CHAPTER 6: API INTERMEDIATE MARKET, BY END USER

CHAPTER 7: API INTERMEDIATE MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

API中間体市場：タイプ別、用途別、エンドユーザー別：世界の機会分析と産業予測、2023-2032年

API Intermediate Market By Type, By Application, By End User : Global Opportunity Analysis and Industry Forecast, 2023-2032

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

第3章 市場概要

第4章 API中間体市場：タイプ別

第5章 API中間体市場：用途別

第6章 API中間体市場：エンドユーザー別

第7章 API中間体市場：地域別

第8章 競争情勢

第9章 企業プロファイル

LIST OF TABLES

LIST OF FIGURES

Key Benefits For Stakeholders

Key Market Segments

By Type

By Application

By End User

By Region

Key Market Players:

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: API INTERMEDIATE MARKET, BY TYPE

CHAPTER 5: API INTERMEDIATE MARKET, BY APPLICATION

CHAPTER 6: API INTERMEDIATE MARKET, BY END USER

CHAPTER 7: API INTERMEDIATE MARKET, BY REGION

CHAPTER 8: COMPETITIVE LANDSCAPE

CHAPTER 9: COMPANY PROFILES

第1章イントロダクション

第2章エグゼクティブサマリー

第3章市場概要

第8章競争情勢

第9章企業プロファイル